Cellosaurus DU145 (CVCL_0105)

Cell line name DU145
Synonyms DU-145; Du-145; DU 145; DU_145; Duke University 145
Accession CVCL_0105
Resource Identification Initiative To cite this cell line use: DU145 (RRID:CVCL_0105)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: JFCR39 cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI60 cancer cell line panel.
Doubling time: 34 hours, at 39th passage (PubMed=631930); 32.3 hours (NCI-DTP); ~29 hours (ATCC); ~30-40 hours (DSMZ).
Microsatellite instability: Instable (MSI-high) (PubMed=23671654; Sanger).
Sequence variation: Homozygous for CDKN2A p.Asp84Tyr (PubMed=17088437).
Sequence variation: Homozygous for RB1 p.Lys715Ter (PubMed=17088437).
Sequence variation: Homozygous for STK11 p.Lys178fs*86 (PubMed=17088437).
Sequence variation: Heterozygous for TP53 p.Val274Phe (PubMed=8104329; PubMed=17088437).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: GPI-anchored proteins analysis by proteomics.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: DU145T; In GEO GSM843494.
Disease Prostate carcinoma (NCIt: C4863)
Derived from metastatic site: Brain.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_1968 (BM-1604); CVCL_J251 (DU-145-Luc); CVCL_4Y36 (DU-145 R); CVCL_AS75 (DU145/RC0.1); CVCL_D639 (DU145/RC1); CVCL_4781 (ND-1); CVCL_4901 (SR DU-145)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): ATCC; CLS; Cosmic-CLP; COG; DSMZ; KCLB; PubMed=11416159; PubMed=14518029; PubMed=17254797; PubMed=19372543; PubMed=25877200; RCB; TKG

Markers:
AmelogeninX,Y
CSF1PO10,11
D13S31712,13,14 (ATCC; CLS; COG; DSMZ; PubMed=14518029; PubMed=25877200)
12,14 (Cosmic-CLP; KCLB; PubMed=17254797; PubMed=19372543; RCB; TKG)
D16S53911,13
D18S5112,13 (CLS)
11,12 (PubMed=14518029)
12 (PubMed=17254797; PubMed=19372543; PubMed=25877200)
D19S43313
D21S1130,33,34 (CLS)
29,30,33 (PubMed=11416159)
30,32,33,34 (PubMed=14518029)
29,30 (PubMed=17254797)
30,33 (PubMed=19372543; PubMed=25877200)
D2S133816
D3S135816
D5S81810,13
D7S8207,10,11 (ATCC; COG; Cosmic-CLP; DSMZ; KCLB; PubMed=14518029; PubMed=17254797; PubMed=25877200)
7,10,11,12 (CLS)
D8S117913,14
FGA22,23 (CLS)
22 (PubMed=14518029; PubMed=17254797; PubMed=25877200)
Penta D9,13
Penta E12,14
TH017
TPOX11
vWA17,18,19 (ATCC; CLS; Cosmic-CLP; PubMed=11416159; RCB)
17,18 (COG; DSMZ; KCLB; PubMed=14518029; PubMed=19372543; PubMed=25877200; TKG)
16,17,18 (PubMed=17254797)
Web pages https://en.wikipedia.org/wiki/DU145
https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://strap.nci.nih.gov/celline_detail.php?sample_id=54
http://capcelllines.ca/details.asp?id=61
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/d/cell-lines-detail-135.html
http://tcpaportal.org/mclp/
Publications

PubMed=631930; DOI=10.1002/ijc.2910210305
Stone K.R., Mickey D.D., Wunderli H., Mickey G.H., Paulson D.F.
Isolation of a human prostate carcinoma cell line (DU 145).
Int. J. Cancer 21:274-281(1978)

PubMed=6244232
Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=8104329; DOI=10.1002/pros.2990230206
Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P.
p53 oncogene mutations in three human prostate cancer cell lines.
Prostate 23:123-134(1993)

PubMed=9018337; DOI=10.1002/(SICI)1097-0045(19970101)30:1<58::AID-PROS9>3.0.CO;2-H
Webber M.M., Bello D., Quader S.T.
Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines.
Prostate 30:58-64(1997)

PubMed=9214606; DOI=10.1093/carcin/18.6.1225
Webber M.M., Bello D., Kleinman H.K., Hoffman M.P.
Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells.
Carcinogenesis 18:1225-1231(1997)

PubMed=10702678; DOI=10.1159/000015432
Pan Y., Kytola S., Farnebo F., Wang N., Lui W.-O., Nupponen N., Isola J., Visakorpi T., Bergerheim U.S.R., Larsson C.
Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping.
Cytogenet. Cell Genet. 87:225-232(1999)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H
Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Mol. Carcinog. 28:236-246(2000)

PubMed=11135431; DOI=10.1002/1098-2264(2000)9999:9999<::AID-GCC1076>3.0.CO;2-E
Aurich-Costa J., Vannier A., Gregoire E., Nowak F., Cherif D.
IPM-FISH, a new M-FISH approach using IRS-PCR painting probes: application to the analysis of seven human prostate cell lines.
Genes Chromosomes Cancer 30:143-160(2001)

PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3
Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.
The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: a comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data.
Cancer Genet. Cytogenet. 124:112-121(2001)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=12615715
Reinhold W.C., Kouros-Mehr H., Kohn K.W., Maunakea A.K., Lababidi S., Roschke A., Stover K., Alexander J., Pantazis P., Miller L., Liu E., Kirsch I.R., Urasaki Y., Pommier Y., Weinstein J.N.
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping.
Cancer Res. 63:1000-1011(2003)

PubMed=12725112; DOI=10.1385/1-59259-372-0:21
Russell P.J., Kingsley E.A.
Human prostate cancer cell lines.
Methods Mol. Med. 81:21-39(2003)

PubMed=14518029; DOI=10.1002/pros.10290
van Bokhoven A., Varella-Garcia M., Korch C., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.
Molecular characterization of human prostate carcinoma cell lines.
Prostate 57:205-225(2003)

PubMed=15486987; DOI=10.1002/pros.20158
Zhao H., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D.
Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
Prostate 63:187-197(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001
Azari S., Ahmadi N., Tehrani M.J., Shokri F.
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Biologicals 35:195-202(2007)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L., Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20-20(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
J. Proteomics 139:77-83(2016)

PubMed=27141528; DOI=10.1016/j.dib.2016.04.001
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Data Brief 7:1302-1305(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20-20(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ATCC; HTB-81
BCRC; 60348
BCRJ; 0078
CLS; 300168/p708_DU-145
DSMZ; ACC-261
ICLC; HTL99013
IZSLER; BS TCL 141
KCB; KCB 200701YJ
KCLB; 30081
NCBI_Iran; C428
NCI-DTP; DU-145
RCB; RCB2143
TKG; TKG 0604
Cell line databases/resources CLDB; cl1108
CLDB; cl1109
CLDB; cl4961
CLDB; cl5184
CCLE; DU145_PROSTATE
CCRID; 3111C0001CCC000006
CCRID; 3131C0001000700080
Cosmic-CLP; 905935
GDSC; 905935
LINCS_LDP; LCL-1146
Lonza; 761
SKY/M-FISH/CGH; 2792
TOKU-E; 1103
Ontologies BTO; BTO:0001332
CLO; CLO_0002840
CLO; CLO_0051536
EFO; EFO_0005441
MCCL; MCC:0000140
Biological sample resources BioSample; SAMN03472017
BioSample; SAMN03472041
BioSample; SAMN03472757
Chemistry resources ChEMBL-Cells; CHEMBL3308034
ChEMBL-Targets; CHEMBL613508
Gene expression databases GEO; GSM2120
GEO; GSM50224
GEO; GSM50288
GEO; GSM91924
GEO; GSM142455
GEO; GSM142456
GEO; GSM482671
GEO; GSM525794
GEO; GSM648818
GEO; GSM648819
GEO; GSM750774
GEO; GSM750834
GEO; GSM784791
GEO; GSM799369
GEO; GSM799379
GEO; GSM799432
GEO; GSM799442
GEO; GSM843494
GEO; GSM886988
GEO; GSM888057
GEO; GSM1153440
GEO; GSM1153441
GEO; GSM1181273
GEO; GSM1181302
GEO; GSM1181306
GEO; GSM1181328
GEO; GSM1374469
GEO; GSM1374470
GEO; GSM1669745
GEO; GSM2124639
Other Wikidata; Q5206280
Polymorphism and mutation databases Cosmic; 688116
Cosmic; 699306
Cosmic; 704850
Cosmic; 721367
Cosmic; 721558
Cosmic; 755299
Cosmic; 759893
Cosmic; 801349
Cosmic; 809223
Cosmic; 809224
Cosmic; 850415
Cosmic; 850824
Cosmic; 869156
Cosmic; 875891
Cosmic; 876395
Cosmic; 897454
Cosmic; 905935
Cosmic; 911998
Cosmic; 918501
Cosmic; 921050
Cosmic; 922550
Cosmic; 923401
Cosmic; 923956
Cosmic; 943177
Cosmic; 948075
Cosmic; 949247
Cosmic; 974300
Cosmic; 1028649
Cosmic; 1028700
Cosmic; 1057758
Cosmic; 1070887
Cosmic; 1071478
Cosmic; 1071905
Cosmic; 1075274
Cosmic; 1092597
Cosmic; 1172627
Cosmic; 1175887
Cosmic; 1176617
Cosmic; 1212490
Cosmic; 1218869
Cosmic; 1305381
Cosmic; 1312368
Cosmic; 1330912
Cosmic; 1436047
Cosmic; 1481419
Cosmic; 1542078
Cosmic; 1689715
Cosmic; 1712065
Cosmic; 1995389
Cosmic; 1998439
Cosmic; 2580127
Cosmic; 2585152
Cosmic; 2585229
Cosmic; 2592487
Proteomic databases PRIDE; PXD003105